CD4CAR

BIOLOGICAL3 trials

Sponsors

Huda Salman

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaT-cell LeukemiaT-cell Lymphoma

Phase 1

CD4CAR for CD4+ Leukemia and Lymphoma

RecruitingNCT03829540

Huda SalmanT-cell Leukemia, T-cell Lymphoma

Start: 2020-07-09End: 2042-12-01Target: 20Updated: 2026-06-24

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

RecruitingNCT06071624

Huda SalmanChronic Myelomonocytic Leukemia

Start: 2024-02-21End: 2043-12-01Target: 30Updated: 2026-06-24

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

RecruitingNCT06197672

Huda SalmanAcute Myeloid Leukemia

Start: 2024-03-19End: 2042-12-01Target: 30Updated: 2026-06-24

Related Papers

Phase I First-in-Human Study on the Feasibility, Safety, and Antitumor Activity of CD4-Redirected Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with CD4+ T-Cell Malignancies (TCM)

Blood2023-11-022 citations

683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)

Regular and Young Investigator Award Abstracts2023-10-31